Table 1.
Clinical and laboratory features of patients at first biopsy
| Variables | Values |
| Number of patients | 112 |
| Age in years (mean ± SD) | 46.9 ± 12.3 |
| Gender (Male/Female) | 65/47 (58%/42%) |
| Age at infection in years (mean ± SD) | 25.8 ± 13.1 |
| Route of infection | |
| Blood transfusion | 52/112 (46.4%) |
| Illegal drug use | 13/112 (11.6%) |
| Other known routes | 28/112 (25.0%) |
| Unknown | 19/112 (17.0%) |
| Duration of infection in years (mean ± SD) | 22.7 ± 10.8 |
| Laboratory | |
| Alanine aminotransferase (× UNL) | 2.96 ± 2.43 |
| Aspartate aminotransferase (× UNL) | 1.74 ± 1.16 |
| Gamma-glutamyltranspeptidase (× UNL) | 1.28 ± 0.97 |
| Serum albumin (mg/dL) | 4.32 ± 0.51 |
| Prothrombin activity (%) | 90.2 ± 9.9 |
| Platelet count (/mm3) | 216 510 ± 68 088 |
| Genotyping of HCV | |
| 1 | 73/105 (69.5%) |
| Non-1 | 31/105 (29.5%) |
| Indeterminate | 1/105 (0.9%) |
| Liver Histopathology | |
| Lymphoid aggregates | 54/112 (48.2%) |
| Ductal injury | 13/112 (11.6%) |
| Steatosis | 58/112 (51.8%) |
| Siderosis | 20/112 (18.0%) |
| IFN Receptors | 79/110 (71.8%) |
| Fibrosis (METAVIR scoring system) | |
| F0 | 19/112 (17.0%) |
| F1 | 41/112 (36.6%) |
| F2 | 25/112 (22.3%) |
| F3 | 6/112 (5.4%) |
| F4 | 21/112 (18.8%) |
| Histological Activity (METAVIR scoring system) | |
| A0 | 27/112 (24.1%) |
| A1 | 53/112 (47.3%) |
| A2 | 24/112 (21.4%) |
| A3 | 8/112 (7.1%) |
| Treatment | |
| Non-treated | 33/112 (29.5%) |
| Treatment responders | 23/112 (20.5%) |
| Treatment non-responders | 56/112 (50.0%) |
UNL: Upper normal limit.